|
|
|
|
||
Re: Shoffner/Meriggioli contextGood point on the DRG issues. I haven't spent much time digging into it after Watsonncrick post but has to be a component of the novel aav bioanalytical work going on. Novartis gets period updates about the novel capsid program but for them to decide which capsid to use they would have to feel very comfortable in the risk assessment. |
return to message board, top of board |